Adalimumab-induced bronchospasm: not a class effect

Janssen, Rob; Krivokuca, I.; Kruize, Aike A.; Koenderman, Leo; Lammers, J.-W. J.

doi:10.1136/thx.2007.086512

Cited by 7 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor necrosis factor (TNF) alpha has been implicated in asthmatic airway inflammation. The pathophysiologic mechanisms of asthma induced by anti-TNF-alpha treatment are unknown (3,4). Asthma symptoms appeared after introduction of anti-TNF-α in two patients who did not appear to be predisposed to the disease.…”

Section: Discussionmentioning

confidence: 99%

“…In most of the adalimumab reported cases the asthma has been mild and adalimumab has not needed to be withdrawn. The details of the asthma adverse events to infliximab and etanercept are not available (1)(2)(3)(4)(5). In the absence of other guidelines, we followed the American Thoracic Society (ATS) guidelines for asthma and added an inhaled steroid, which completely resolved the patient's symptoms but we stopped adalimumab in case (2).…”

Section: Discussionmentioning

confidence: 99%

“…Asthma appears to be a definite but rare side-effect of anti-TNF blockade . Asthma symptoms appeared after introduction of anti-TNF-α in two patients who did not appear to be predisposed to the disease (1)(2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adalimumab and etanercept induced asthma

Dagli

Akgedik

Yıldırım

et al. 2015

1.11 Clinical Problems - Asthma

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adalimumab and etanercept induced asthma

Dagli

Akgedik

Yıldırım

et al. 2015

1.11 Clinical Problems - Asthma

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Adalimumab

2016

Meyler's Side Effects of Drugs

View full text Add to dashboard Cite

Adalimumab-induced bronchospasm: not a class effect

Cited by 7 publications

References 4 publications

Adalimumab and etanercept induced asthma

Adalimumab and etanercept induced asthma

Current awareness: Pharmacoepidemiology and drug safety

Adalimumab

Contact Info

Product

Resources

About